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Central venous catheter-related infections have been
associated with high morbidity, mortality, and costs. Catheter
use in chronic hemodialysis patients has been recognized as
distinct from other patient populations who require
central venous access, leading to recent adaptations in
guidelines-recommended diagnosis for catheter-related
bacteremia (CRB). This review will discuss the epidemiology
and pathogenesis of hemodialysis CRB, in addition to a
focus on interventions that have favorably affected CRB
outcomes. These include: (1) the use of prophylactic topical
antimicrobial ointments at the catheter exit site, (2) the use of
prophylactic catheter locking solutions for the prevention of
CRB, (3) strategies for management of the catheter in CRB,
and (4) the use of vascular access managers and quality
initiative programs.
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BACKGROUND
Vascular access is not only known as the obvious ‘Achilles
heel’ of hemodialysis (HD) but it is also the quiet
undercurrent of trends in patient outcomes. This is apparent
when one follows the growth and impact of the central
venous catheter (CVC) over two decades since its introduc-
tion as a ‘permanent’ access in the mid-1980s.1–3 At present,
the prevalent CVC use has increased to B25% while 480%
of patients initiate HD with a catheter.4 When such large
numbers are affected, trends in patient outcomes serve to
highlight the catheter’s associations with high morbidity and
mortality. For example, the most recent USRDS (US Renal
Data System) report observed high first- and second-month
death rates after HD initiation, coincident with the increase
in CVC placement rates.5 A significant cause of CVC-related
morbidity and mortality is infection. For example, rates of
mortality from infection in the first year of HD are now 2.4
times greater than in 1981 and is largely attributed to CVC
use.5 Hospitalizations due to vascular access infections more
than doubled between 1993 and 2005 in the United States6
and mirror the marked increase in CVC use during the same
period, suggesting that increased hospitalization may not be
solely attributable to poor CVC care but due to increased
CVC use itself. Catheter-related infections encompass exit site
infections, tunnel infections, and bacteremias; however,
bacteremias are the most clinically important because of
their common occurrence and potential to transform into
sepsis. The risk of sepsis with a CVC is twofold to fivefold
higher than that with arteriovenous grafts and arteriovenous
fistulae.7 After an episode of sepsis, the rate of adverse
cardiovascular events increases by up to twofold. These
include myocardial infarction, congestive heart failure,
peripheral vascular disease, and cerebral vascular accident
events.8 Unquestionably, CVC-related infections and sepsis
are associated with high morbidity and hospitalization rates,
high treatment costs, and poor survival.5,8–14 However,
welcome relief has been observed in the USRDS 2009 data
with a recent decline (2006–2007) in overall vascular access-
related hospitalizations due to infection, but they are still
approximately two times higher than a decade before.5
The hopeful speculation for this improved trend is of a height-
ened awareness of the high risks associated with catheter-related
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bacteremia (CRB) and the implementation of evidence-based
preventative and management strategies along with other quality
improvement measures. This paper will review the epidemiology
and pathophysiology of CRB and emphasize evidence-based
strategies to prevent and manage CRB.
EPIDEMIOLOGY
Diagnosis
Given the gravity of CRB in HD patients dialyzing with a
catheter access, a precise diagnosis and definition of CRB
would seem crucial. However, this seemingly basic require-
ment has been challenging because of the unique circum-
stances of HD patients, whereby the rigorous standard
of requiring quantitative blood cultures and/or determining
differential time to positivity from a peripheral vein and
catheter blood culture cannot be obtained because of logistic
or other reasons.15 For example, the priority of preserving
arm veins for future fistula creation, fragile and damaged
vessels, and patient refusal render venipuncture impractical.
The IDSA (Infectious Disease Society of America) has
recently acknowledged these significant challenges, and
provision has been made to accept blood cultures obtained
from the catheter and blood line connected to the CVC
(instead of peripheral vein venipuncture) when peripheral
vein samples are not possible. Drainage at the CVC exit site
should be cultured as the diagnosis of CRB is strengthened by
a positive culture of the same organism at the exit site and in
the blood. However, there is often no drainage at the exit site.
Therefore, when there is an absence of drainage at the exit
site and alternate sources of infection cannot be found,
positive blood cultures obtained from an HD catheter should
be considered a possible CRB in a symptomatic patient and
treated as such, with initiation of antimicrobial therapy.15
Although this is only considered a ‘possible’ CRB by precise
IDSA standards, it is an appropriate definition of HD CRB.
The CDC has recently provided definitions and tools for
dialysis units for the reporting of dialysis vascular access
infections as ‘dialysis event/100 patient-months’ for surveil-
lance purposes.16 However, reporting of CRB as event/1000
catheter days has been recognized as the most informative
measure, and can be used for benchmarking, clinical
monitoring, surveillance, and investigational studies, but
requires appropriate resources for accuracy.17 Tracking of
CRB has been recognized as an important aspect of dialysis
patient care18–23 and has been recently recommended as a
clinical performance measure by a CMS clinical technical
expert panel as part of monitoring dialysis access-related
infections (http://www.cms.gov/CPMProject/Downloads/
ESRD2010TechnicalExpertPanelReport.pdf).
Rates, risk factors, and pathogens
The incidence of CRB ranges between 0.6 and 6.5 episodes
per 1000 catheter days.14,24–36 The majority of CRB-
associated isolates are Gram-positive organisms (52–84%),
with Staphylococcus aureus accounting for between 21 and
43% in most series, and methicillin-resistant S. aureus
(MRSA) reported in approximately 12–38%.14,24,25,27,37 Risk
factors for CRB that have been identified include poor
patient hygiene, previous CRB, recent hospitalization, longer
duration of catheter use, inadequate dialysis, hypoalbumine-
mia, S. aureus nasal carriage, diabetes mellitus, immuno-
compromised status, atherosclerosis, and hypertension.37–41
Serious metastatic infectious complications occur in 3–44% of
episodes, and include endocarditis, osteomyelitis, thrombophle-
bitis, septic arthritis, spinal epidural abscess, and large atrial
thrombi13,14,25,34,37,42–44 (Table 1). The incidence of infectious
complications is higher when catheter salvage is attempted.13,44
Epidural abscess and large atrial thrombi occur uncommonly,
and are usually associated with Staphylococcus isolates and with
Table 1 |Metastatic complications of catheter-related
bacteremia (CRB)
Complication
Frequency
(%) References
Endocarditis 3–17 Engemann et al.9; Mokrzycki et al.13;
Tanriover et al.14; Saad24; Marr et al.37
Large atrial thrombi Rare Negulescu et al.42; Ghani et al.45;
Kingdon et al.138; Shah et al.139
Spinal epidural abscess Rare Kovalik et al.44; Obrador and
Levenson46; Philipneri et al.47
Septic pulmonary
emboli
0.4 Mokrzycki et al.13
Septic emboli other
organs (for example,
the brain)
1–2 Engemann et al.9; Tanriover et al.14
Other abscess 1.5 Mokrzycki et al.13
Septic arthritis 2–5 Tanriover et al.14; Marr et al.37
Osteomyelitis 1.5–15 Engemann et al.9; Mokrzycki et al.13;
Marr et al.37
Death 6–34 Marr et al.10; Mokrzycki et al.13;
Lok et al.27; Lentino et al.57;
Inrig et al.58; Lowy140
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Figure 1 |Two-dimensional transesophageal echocardiogram
image of the mitral valve (MV), anterior MV leaflet (m), and
posterior MV leaflet (mm) with a vegetation (*) attached by a
stalk to the left atrial (LA) side of the posterior MV leaflet,
near its tip. LV, left ventricle.
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poor outcomes. These include severe neurological deficits, such
as paresis and paralysis (50–72%) with epidural abscess, septic
pulmonary emboli with large atrial thrombus (Figures 1–4), and
high mortality rates (17–60%).42,44–47
The rate of S. aureus nasal carriage due to S. aureus in the
HD population ranges between 11 and 57%, and is associated
with a threefold higher relative risk of developing S. aureus-
related CRB.27,28,48–55 S. aureus is a particularly lethal
microbiologic isolate, and the annual incidence of S. aureus
bacteremia in HD patients is between 6 and 27%.54,56
S. aureus CRB is associated with a more than threefold higher
rate of infectious complications, and a fourfold greater risk of
recurrent bacteremia or septic death in 3 months, relative to
other microbiologic isolates.13 The mortality rate associated
with S. aureus access infections has been reported to be
as high as 30%.9,57,58 In some HD units, up to one-third of
CRBs are caused by MRSA, which has been demonstrated to
be associated with greater costs and three to five times higher
mortality compared with methicillin-sensitive strains.59
Gram-negative species are isolated in 27–36% of episodes
and fungal isolates are less common (p10%).13,25,34,37
Pseudomonas/Stenotrophemonas species account for 4–16%
of CRB isolates in HD patients.24,27,60 In contrast to the high
mortality rates reported in Pseudomonas sepsis associated
with visceral nosocomial infections (non-CRB), Golestaneh
et al.60 reported favorable outcomes and no deaths in
18 episodes of Pseudomonas HD CRB, likely due to catheter
removal in 89% of cases. Multiple organisms may be present
in 7–21% of CRB cases27,34,43 and are particularly challenging
to treat.61
PATHOGENESIS
There are two main routes by which organisms gain entry
into the bloodstream to cause CRB: an extraluminal pathway
and an intraluminal pathway.62 The extraluminal pathway
involves initial contact between skin surface organisms and
the external surface of the catheter at the time of insertion or
thereafter, before complete exit site healing and endothelia-
lization of the subcutaneous tunnel (Figure 5). Consequently,
organisms can colonize or migrate down the intercutaneous
180140
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Figure 2 | Three-dimensional transesophageal echocardiogram
image of the open mitral valve seen en face from the LA with
the aortic valve at 12 o’clock (‘surgeon’s view’). A large
vegetation (*) is seen attached to the (mm) posterior MV leaflet,
(m) anterior MV leaflet, (#) lateral, and (##) medial MV annulus
after LA cropped. LA, left atrial; MV, mitral valve.
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Figure 3 | Two-dimensional transesophageal echocardiogram
image of the aortic valve in mid-systole with opening of the
non-coronary cusp (mm) and the right coronary cusp (m). A
large vegetation (*) is attached to the aortic (Ao) side of the non-
coronary cusp, with an associated perforation (thick arrow) of the
cusp. LA, left atrial; LVOT, left ventricular outflow tract.
Figure 4 |Autopsy image of a large cardiac valvular
vegetation.
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exterior tract of the catheter to the tip where hematogenous
spread occurs with blood flow perturbation, exacerbated by
dialysis, and leads to CRB. The intraluminal pathway involves
transfer of organisms by contact from the hands of
individuals (usually health-care workers) accessing the CVC
or the patient’s skin/surrounding clothing to catheter hubs or
caps, resulting in the contamination of internal catheter
surfaces. The extraluminal pathway tends to predominate
early on after CVC insertion, whereas the potential for
organism entry through the intraluminal route persists
for the entire catheter lifespan. Regardless of the route, once
entry is gained, the organism may adhere directly to the CVC
surface or may become incorporated within a fibrin sheath;
this sheath envelopes the CVC to variable extents and often
develops within 24 h of CVC insertion.63 The critical
adherence of the organism to the catheter surface initiates
the common pathway of biofilm production. A mature
biofilm is a unique self-sustaining community of micro-
organisms protected by an exopolysaccharide matrix
that is stimulated and secreted by the microorganisms.64,65
It is noteworthy that close examination of catheters by
scanning electron microscopy has demonstrated universal
endoluminal coverage of material consistent with biofilm but
without universal colonization by bacteria.66 This is in
contradiction to previous findings and teachings of universal
CVC microbial colonization;67 such a discrepancy is likely
due to the ability of advanced technology to distinguish
minute biological material from bacteria. This non-colonized
biofilm-like material is distinctly different by the absence of
microorganisms and should be termed simply as ‘fibrin
sheath’ or ‘adherent biological material’. Common micro-
organisms found in biofilms include Staphylococcus, Candida,
Pseudomonas, and others64,65 (Figure 6). The mature multi-
layered biofilm’s exopolysaccharide shell may be 100-fold
larger than the microorganisms that it protects,68 and acts as
a superresistant barrier to antibiotic penetration and action.
Some mechanisms for antibiotic resistance include the
ability of the glycomatrix to react with and neutralize the
antimicrobial agent, in addition to providing an effective
diffusion barrier to the antimicrobial agent and other
multicellular strategies.69,70 The dynamic characteristics of
the biofilm facilitate sustained infection and subsequent
hematogenous dissemination of the infecting organism.
Clearly, the critical step in the management of CRB is the
prevention of microorganism adherence to the catheter and
biofilm development.
PREVENTION
Core prophylactic CRB measures begin with the routine
CVC care performed by the HD staff at each dialysis session.
Both the patient and the HD staff should follow universal
precautions and hygienic measures. KDOQI (Kidney Disease
Outcomes Quality Initiative) recommends that staff manip-
ulating catheters should wear a mask and clean or sterile
disposable gloves;20 the data supporting masks are extra-
polated from studies of their use during CVC insertion.71,72
Acceptable exit site cleaning solutions are chlorhexidine 2%
and alcohol 70% or povidone-iodine 10% solution;20,73,74
comparative studies of these two antiseptics have been per-
formed in various populations requiring CVC use. Rando-
mized studies and meta-analysis demonstrate superior
antisepsis with chlorhexidine,75–80 whereas povidone-iodine
and alcohol remain effective alternatives if chlorhexidine
cannot be used. Recent data indicate that there is no
significant difference between transparent, semi-permeable
dressings, and standard gauze dressings with respect to
catheter exit site colonization or CRB.81–84
The routine application of topical antibiotic ointments
at the CVC exit site has been shown to be associated with a
75–93% reduction in the risk of CRB.27,49–51 Topical
ointments that have been studied include mupirocin,
povidone-iodine, and polysporin triple antibiotic ointment.85
Figure 5 | Exit site infection. Erythema and purulent discharge is
evident at the catheter exit site.
× 800 10 µm
Figure 6 | S. aureus biofilm detected by scanning electron
microscopy. Picture courtesy of Lavern M. Vercaigne, Faculty of
Pharmacy, University of Manitoba. S. aureus, Staphylococcus
aureus.
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Medical-grade honey has antimicrobial effects against both
resistant bacteria, protozoa, viruses, and fungi.86 This is
mediated by its high osmolarity, low water content, acidic
pH(3.2–4.5), the generation of hydrogen peroxide upon its
dilution, as well as its flavonoid and phenolic acid contents.87
It has been shown to have equivalent efficacy as mupirocin
for CRB prophylaxis.28,29 Table 2 summarizes the details of
six clinical trials using prophylactic topical agents in HD
catheters.
Mupirocin nasal decolonization in HD patients has also
been shown to reduce the rate of S. aureus bacteremia
by 78%, and is cost effective, but may require repeat
applications.52,53,88,89 The reported risk of developing
mupirocin resistance with short-term use is low; this includes
a study treating HD patients with S. aureus nasal carriage.52
High-level mupirocin resistance has been reported in 8–25%
S. aureus isolates in peritoneal dialysis patients when used for
long-term prophylaxis at the exit site. Mupirocin-resistant
strains were isolated in 3–16% of the peritoneal dialysis
population in these studies.90–92 Despite its efficacy, mupir-
ocin is not routinely used in the HD population because of
concerns of emergence of resistance. In contrast, there are
currently no reports in the literature of microbial resistance
to other prophylactic agents applied to the exit site, such as
povidone-iodine in dialysis patients. A 6-year prospective
follow-up study using a polysporin triple ointment applica-
tion at the exit site of HD catheters has not demonstrated
microbial resistance or loss of efficacy for infection
prophylaxis, with bacteremia rates consistently o1.0/1000
catheter days.85 Microbial resistance to honey has never been
reported, also rendering it a promising future topical agent
for CRB prophylaxis.
There are 25 clinical trials evaluating prophylactic
antimicrobial locking solutions (ALSs) for the reduction of
CRB in HD patients and the results are summarized in
Table 3. Detailed comparisons of prophylactic ALSs have
Table 3 | Summary of clinical trials using prophylactic antimicrobial lock (AML) for catheter-related bacteremia (CRB)
associated with hemodialysis catheters (CVC)
First author, year
Subject
number Antimicrobial lock (AML)
Controls (C)
(U/ml)
CRB rate AML vs
C/1000 CVC days P-value
Pervez, 200297 36 Gentamicin 20mg/ml+citrate 4.67% Heparin 1000 0.62 vs 2.11 NA
Dogra, 2002142 83 Gentamicin 27mg/ml+citrate 1% Heparin 5000 0.3 vs 4.2 0.0003
McIntyre, 2004143 50 Gentamicin 5mg/ml+heparin 5000U/ml Heparin 5000 0.3 vs 4 0.02
Nori, 2006144 30 Gentamicin 4mg/ml+citrate 3.13%; or Heparin 5000 0 vs 4 0.008
Venditto, 2010109 265 Gentamicin 2mg/ml+heparin 5000U/ml Heparin 5000 0.4 vs 2.9 0.06
Onder, 2009145 43 Tobramycin 5mg/dl+TPA 1mg/ml Heparin 5000 6.2 vs 16.8 0.2
Bleyer, 2005146 60 Minocycline 3mg/ml+EDTA 30mg/ml Heparin (dose NA) 0 vs 0.47 0.35
30 Minocycline 3mg/ml+EDTA 30mg/ml Heparin 5000 0.4 vs 4 0.02
Saxena, 2005147 96 Cefotaxime 10mg/ml+heparin 5000U/ml Heparin 5000 1.65 vs 3.13 NA
Saxena, 2006148 113 Cefotaxime 10mg/ml+heparin 5000U/ml Heparin 5000 1.44 vs 3.15 o0.001
Al-Hwiesh, 2007149 63 Vancomycin 25mg/ml+gentamicin 40mg/ml+heparin
5000U/ml
Heparin 5000 4.54 vs 13.11 0.05
Kim, 2006150 120 Cefazolin 10mg/ml+gentamicin 5mg/ml+heparin
1000U/ml
Heparin 1000 0.44 vs 3.12 0.031
Allon, 200335 50 Taurolidine 1.35%+citrate 4% Heparin 5000 0.6 vs 5.9 o0.001
Betjes, 2004108 58 Taurolidine 1.35%+citrate 4% Heparin 5000 0 vs 2.1 0.047
Solomon, 201033 110 Taurolidine 1.35%+citrate 4% Heparin 5000 1.4 vs 2.4 0.1
Weijmer, 200530 291 Trisodium citrate 30% Heparin 5000 1.1 vs 4.1 o0.001
Winnett, 2008110 413 Trisodium citrate 46.7% Heparin 5000 0.81 vs 2.13 o0.001
Power, 200931 232 Trisodium citrate 46.7% Heparin 5000 0.7 vs 0.7 0.9
Venditto, 2010109 265 Trisodium citrate 46% Heparin 5000 3.4 vs 2.9 NS
Abbreviations: CRB, catheter-related bacteremia; CVC, central venous catheter; EDTA, ethylenediaminetetraacetic acid; NA, not available; NS, non-significant; TPA, tissue
plasminogen activator.
Table 2 | Summary of clinical trials using topical medicinal barriers at the exit site for prophylaxis of catheter-related
bacteremia in hemodialysis patients
First author,
year Prophylactic agent Comparator n Outcome
Bacteremia/1000
catheter days
Rate ratio
(95% CI) P-value
Levin, 199949 Povidone-iodine (PI) No ointment (N) 129 CRB 0.4 (PI) vs 4.6 (N) 0.07 (0.06–0.24) o0.01
Sesso, 199850 Mupirocin (M) No ointment (N) 136 S. aureus CRB 0.71 (M) vs 8.92 (PI) 0.14 (0.03–0.63) o0.001
Johnson, 200228 Mupirocin (M) No ointment (N) 50 CRB 1.6 (M) vs 10.5 (N) 0.15 (0.03–0.8) o0.01
Lok, 200327 Polysporin triple (PO) Placebo (P) 169 CRB, death 0.63 (PO) vs 2.48 (P)
4% (PO) vs 16% (P)
0.25 (0.19–0.34) 0.0004
0.0004
Johnson, 200529 Medihoney (H)a Mupirocin (M)a 101 CRB 0.97 (H) vs 0.85 (M) 0.94 (0.27–3.24) 0.92
Abbreviations: CI, confidence interval; CRB, catheter-related bacteremia; H, medihoney; HD, hemodialysis; M, mupirocin; N, no ointment; P, placebo; PI, povidone-iodine;
PO, polysporin triple antibiotic; S. aureus, Staphylococcus aureus.
aEquivalent efficacy.
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been published in several recent meta-analyses and
reviews.93–96 A marked reduction in CRB is associated with
the use of ALS (range: 51–99%). In a recent systematic review
of 9 randomized controlled trials, the CRB baseline risk was
3.0/1000 CVC days; the benefit of ALS corresponded to a
number needed to treat of 3 patients to prevent 1 CRB with
an average CVC insertion time of 146 days (range: 37–365).96
However, analysis of studies does reveal the potential
presence of publication bias, whereby studies with less
beneficial effect and larger sample sizes are less likely to be
published. Furthermore, caution is required because of the
potential threat of antibiotic resistance with prolonged ALS
prophylaxis. Although in previous trials of ALS, only one case
of gentamicin resistance has been reported, there has been a
recent report of emergence of gentamicin-resistant Gram-
positive organisms with long-term prophylactic use of
gentamicin locks in HD catheters.97,98 In a study by Landry
et al.,98 gentamicin–heparin ALS was associated with 29 cases
of gentamicin-resistant Gram-positive bacteremia, required a
relatively long period of time (mean 25 days) before blood
cultures cleared, and were associated with a 21% mortality
rate in 2 months.
The use of non-antibiotic locks would be a desirable
solution to address the problem of antibiotic resistance.
Solutions demonstrated to effectively eradicate biofilm
include EDTA (ethylenediaminetetraacetic acid), trisodium
citrate at concentrations 40.5%, taurolidine, and ethanol.
They have been demonstrated to effectively reduce biofilm by
a number of mechanisms, including the chelation of metallic
cations (namely Ca2þ , Mg2þ , and Fe3þ ) required for
biofilm development.99–107 However, not all solutions have
undergone clinical trials. Initial studies using a non-antibiotic
ALS (taurolidine 1.35%-citrate 4%) reported 90–99% reduc-
tion in the incidence of CRB, although a recently published
trial found no difference in time to first CRB.33,35,108
Furthermore, an increase in the utilization of thrombolytic
therapy has been reported with taurolidine-citrate.33,35 The
data on CRB reduction with higher concentrations of
trisodium citrate (between 30 and 46.7%) are conflicting.
Initial studies reported a 62–75% risk reduction in CRB
incidence using 30% citrate ALS; however, 2 recently
published clinical trials report no benefit of using 46.7%
citrate ALS.30,31,109,110 In 2000, the US FDA (Food and Drug
Administration) issued a warning against the use of high-
dose citrate lock because of a reported death associated with
46.7% citrate with excessive overfill,111 which led to a
manufacturer’s recall of this product. Recently, hypertonic
citrate (43%) solutions have been associated with sympto-
matic pulmonary and cerebral embolisms, likely due to
seepage from multiple side holes and exacerbated by the
solution’s hyperosmolarity.112 Clearly, caution must be
exercised when using high-concentration citrate lock. How-
ever, other novel antimicrobial locks have demonstrated the
ability to reduce biofilm;101,103,113 preliminary clinical trial
safety and efficacy data seem promising and final results are
expected in the near future.
Intraluminal surface modification is another strategy to
limit or eradicate biofilm and prevent CRB. Inherent
intraluminal irregularities can promote lodgment of organ-
isms into the catheter surface and also promote biofilm
formation.114,115 A recent randomized cross-over study has
demonstrated that a surface-modifying additive limited
catheter surface breakdown, improved surface irregularity,
and reduced bacterial growth compared with catheters
without surface modification.116 Alternatively, impregnating
catheters with antiseptic or antimicrobial agents such as
chlorhexidine, silver sulfadiazine, and minocycline/rifampin
has demonstrated reductions in microbial colonization and
CRB in non-dialysis patients,117–120 but their short activity
may not be generalizable to the chronic CVC use required in
HD patients. No benefit was observed in a randomized study
of 91 HD patients who received dialysis through silver-
treated catheters.121 Other agents, not typically known for
their antimicrobial properties, may hold promise. Bismuth
has been demonstrated to have antibiofilm and antibiotic
properties;122,123 a single randomized clinical trial of
bismuth-coated temporary non-tunneled HD catheters in
77 patients showed a reduction in catheter colonization
compared with non-coated catheters.124 Further studies with
clinical outcomes using long-term tunneled catheters coated
with bismuth will be elucidating. Finally, although heparin is
traditionally used as an anticoagulant, two clinical studies of
heparin-coated catheters have been associated with low rates
of CRB but did not improve overall CVC patency.125,126 This
is somewhat surprising as heparin has been demonstrated to
enhance S. aureus biofilm formation on CVC surfaces.99
However, the overriding anticoagulant properties of heparin
might inhibit thrombus and fibrin sheath formation, limiting
the nidus upon which a biofilm forms. This highlights the
importance of the microorganism’s potential contact surface
and catheter surface modification as a promising area of
future research.
TREATMENT OF CRB
Antibiotic therapy
Initial empiric antibiotic therapy usually includes a
broad-spectrum coverage for both Gram-positive and
Gram-negative organisms. Owing to the high prevalence of
MRSA in the HD setting, empiric therapy should include
coverage for MRSA. Vancomycin or teicoplanin may be used.
Published vancomycin protocols127–129 may be adopted to
encourage safe and effective administration. However, when
the minimum inhibitory concentration for vancomycin
exceeds 2 mm/ml, alternative antibiotics, such as daptomycin,
should be used.15,130 Patients found to have methicillin-
sensitive S. aureus should be changed to cefazolin if there is
no allergic contraindication.15,131 Empiric Gram-negative
coverage should be based on local antibiotic sensitivities.15
Subsequent antibiotics are prescribed according to the
identification and sensitivities of the isolate. When the
organism is susceptible to more than one antibiotic,
preference should be given to antibiotics with a pharmaco-
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kinetic profile that allows for administration at the end of
dialysis to improve patient compliance and treatment efficacy.
Examples of such antibiotics include vancomycin, cefazolin,
ceftazidime, and daptomycin. Furthermore, the presence of
residual renal function should be considered when determin-
ing the choice, dose, and frequency of antibiotics. For example,
aminoglycosides should be avoided in Gram-negative bacter-
emia if a patient has residual renal function and is sensitive to
third-generation cephalosporins. The newly published IDSA
guidelines for long-term catheter-related infections recom-
mend 4–6 weeks of antimicrobial therapy for uncomplicated
S. aureus CRB, 7–14 days for CRB with Gram-negative bacilli
or enterococcus, and a minimum of 14 days for CRB
with Candida species. Complicated CRB characterized by the
presence of septic thrombophlebitis and/or endocarditis
should be treated for 4–6 weeks, whereas osteomyelitis
should be treated for a minimum of 6–8 weeks.15
Catheter management
Catheter removal with delayed CVC replacement is required
in (1) clinically unstable patients, (2) when a persistent fever
is present after 48 h, (3) when a tunnel infection is present,
(4) or if a metastatic infectious complication is present. In
clinically stable patients, in addition to systemic antibiotic
therapy, the strategies for CVC management that have been
studied include catheter salvage without antibiotic lock
(SVG), catheter removal with delayed replacement (DR),
catheter exchange over wire (CEX), or catheter salvage with
antibiotic lock (ABL). The latter three strategies address the
removal or eradication of microorganisms embedded in the
catheter biofilm. When ABL is used for the treatment of CRB,
concentrated antibiotic–anticoagulant solutions are instilled
into the catheter lumen during the interdialytic period at
concentrations 100-fold higher than the respective therapeu-
tic plasma concentrations. In general, although CVC salvage
has been attempted with some success, it is more often
associated with high failure rates (465%) and should be
avoided.37,44,132,133 Catheter salvage is the most costly way of
managing CRB, predicted to be associated with approxi-
mately twofold higher expected total costs.134
Studies reporting the outcomes of catheter management
strategies are summarized in Tables 4 and 5. A comparison of
outcomes reported by individual studies is difficult because of
the fact that most are prospective, uncontrolled studies in which
catheter management decisions were not based on the same
clinical criteria, and because of differences in both study
methodology and the definitions of treatment failure. Blood
cultures should be obtained even after completion of an
antibiotic course in those patients in whom there is suspected
persistent infection. If these blood cultures are positive, the
catheter should be removed and a new tunneled catheter be
placed only after additional negative blood cultures are obtained.
Vascular access teams
The use of a designated vascular access nurse (VAN) manager
in conjunction with evidence-based guidelines to assist
Table 4 | Studies evaluating catheter management for the treatment of catheter-related bacteremia in hemodialysis patients
First author, year
Study
design n
Catheter
management Treatment Definition of success % Success Comment
Capdevila, 1993133 R 13 Salvage Salvage Afebrile in 48 h,
infection-free catheter
survival
100% (Salvage) Only 15% of
isolates were
S. aureus
Marr, 199737 P 62 Salvage Salvage Catheter still present
after 90 days or removed
for non-infectious
etiology
32% (Salvage)
Beathard, 199934 P 77 Exchange vs
removal
with delayed
replacement (DR)
CEX/existing tunnel
(ET)
(no tunnel or exit site
infection)
CEX/new tunnel (NT)
(tunnel or exit site
infection)
DR
No recurrence of
bacteremia in 45 days
87.8% (CEX/ET)
75% (CEX/NT)
86.5% (DR)
P=NS
Saad, 199924 P 73 Salvage vs
exchange
Salvage
CEX
No recurrence of
bacteremia, fever, or
symptoms in 30 days
36.7% (Salvage)
81.4% (CEX)
P=0.0005
Tanriover, 200814 R 69 Exchange vs
delayed removal
CEX
DR
Infection-free catheter
survival in 30 days
B78% (CEX)
B80% (DR)
P=NS
Mokrzycki, 2006135 P 219 Salvage vs
exchange vs
delayed removal
Salvage
CEX
DR
No recurrence of
bacteremia or death
from sepsis in 90 days
74% (Salvage)
97% (CEX)
89% (DR)
P=0.002
Ashby, 2009132 P 208 Salvage vs
delayed removal
Salvage
DR
No recurrence of
bacteremia or
complication in 180 days
66.1% (Salvage)
91% (DR)
Po0.001
Abbreviations: CEX, catheter exchange over wire; DR, delayed reinsertion of catheter; NS, non-significant; S. aureus, Staphylococcus aureus.
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physicians in the management of CRB in the outpatient HD
unit has been shown to reduce treatment failure rates
and septic death, largely due to a reduction in CVC salvage.
In an interventional controlled trial prospectively following
233 episodes of CRB, the addition of a designated VAN
was associated with a significantly lower treatment failure
rate (recurrent bacteremia with the same isolate in 3 months)
compared with controls (VAN: 6% vs control 18%,
P¼ 0.015).135 The intervention was also associated with a
significantly lower rate of death due to sepsis (VAN: 0 vs
control 6%, Po0.02). Similar results were reported by Shiell
et al.136 in a prospective cohort study of 158 patients with
catheters, in which introduction of a multidisciplinary CVC
care team was associated with a significant reduction in non-
elective CVC removal (odds ratio¼ 0.59, confidence interval:
0.36–0.96, P¼ 0.035), largely attributable to reductions in
CVC loss due to infection (65% decline).12,58 The most
effective intervention for reducing catheter-related infections
is the complete avoidance of a CVC vascular access.
Implementation of a VAN and an algorithm in the predialysis
setting has been shown to be efficacious in increasing the use
of arteriovenous fistulae as first vascular access upon HD
initiation (34% increase, P¼ 0.007) and in reducing the total
number of CVC days by 40%.137
COSTS
The economic impact of CRB is considerable. In contrast to
arteriovenous fistulae, catheters are associated with 25%
higher total costs, much of which are excess expenditures for
the treatment of CRB.5 Two centers reported data from the
mid-1990 to 2001 and demonstrated that the mean cost of
treating CRB in hospitalized HD patients was approximately
$23,000–$24,000, including readmissions and outpatient
costs over 12 weeks.9,58 Although a recent retrospective study
performed in 2005 reported similar costs,12 it is important to
note that in general, costs for vascular access infection
have been on the rise since the late 1990s and are currently
35% greater than in 1998.5 Furthermore, S. aureus is
associated with higher health-care costs, particularly
when associated with a complication requiring hospital
Table 5 | Studies evaluating antibiotic lock for the treatment of CRB in hemodialysis patients
First author,
year
Study
design
n
analyzed
Catheter
management Treatment Definition of success % Success Comments
Krishnasami,
200225
P 62 ABL/heparin ABL (gentamicin
1 g/ml or
vancomycin 2.5mg/
ml or cefazolin
5mg/ml)+
heparin
(2500U/ml)
Clinical cure: absence
of fever/chills and
hemodynamic
stability by 48 h or
posttreatment
surveillance blood
cultures negative
64.5% Catheter survival similar
to historical controls
whose CVC was
replaced, 64 vs 54 days;
P=NS; candidemia
excluded from study
protocol
Poole, 200443 P 47 ABL/heparin ABL (vancomycin
2.5mg/ml or
cefazolin 5mg/ml
or ceftazidime
5mg/ml)+
heparin
(2500U/ml)
Clinical cure: absence
of fever and
hemodynamic
stability by 48 h or
posttreatment
surveillance blood
cultures negative
All patients: 70%
GN: 87%
S. epi: 75%
S. aureus: 40%
Infection-free catheter
survival better than
historical controls whose
CVC was replaced, 154 vs
71 days; P=0.02
(enterococcus and
Candida excluded from
the protocol)
Onder, 200861 R 76 ABL/TPA TPA (2mg/2ml)+ABL
(vancomycin
5mg/ml or
tobramycin 5mg/ml)
Successful CRB
clearance at 2 weeks
83% Short-term
success
Worse outcomes with
polymicrobial CRBs
Infection-free survival
at 6 weeks
75% Long-term
success
Onder, 200826 RCT 24 ABL/TPA vs
ABL/heparin
TPA (2mg/2ml) vs
heparin (5000U/ml)+
ABL (vancomycin
5mg/ml or
tobramycin 5mg/ml)
Successful CRB
clearance at 2 weeks
(short-term success)
100% Short-term
success
Fungal infections
excluded
Days infection-free
catheter survival
(long-term success)
ABL/TPA: 126
days vs
ABL/heparin: 154
days
(P=NS)
Equivalent outcomes;
6/24 (25%) had
recurrence of symptoms
within 6 weeks
Beigi 2010151 P 67 ABL ABL (vancomycin
5mg/ml)
Catheter removal
(failure)
96% Heparin was not used as
the anticoagulant;
whether citrate or other
used was unspecified
Abbreviations: ABL, antibiotic lock; CRB, catheter-related bacteremia; CVC, central venous catheter; GN, Gram-negative organism; NS, non-significant; S. epi, Staphylococcus
epidermidis; S. aureus, Staphylococcus aureus; TPA, tissue plasminogen activator.
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admission (B$32, 500),12,58 or if due to MRSA.59 The estimated
expenditures for CRB treated in the outpatient setting would be
expected to be considerably lower (o66% for hospital costs),
between $7000 and $15,000 per episode.9,134 Prevention of CRB
and reduction in catheter use overall are paramount to cost
containment of the health-care budget for HD.
CONCLUSIONS
Catheter-related bacteremia is a significant cause of poor
health outcomes in infected HD patients; however, recent
declines in catheter-related infectious morbidity suggest
efficacy in evidence-based prophylactic and management
strategies. Topical ointments act as a barrier to limit the
extraluminal route of organism entry and have been proven
to prevent CRB. Intraluminal strategies to prevent CRB
include interdialytic ALSs that also have clinical trial-based
proven efficacy. However, justified concerns regarding the
emergence of antibiotic-resistant organisms have led to the
development of novel antimicrobial lock solutions that are
promising. The diagnosis of CRB is challenging and unique
in the HD population. CRB surveillance and management
can be effectively facilitated by multidisciplinary vascular
access teams to further reduce CRB rates and complications,
and use of catheters in HD patients.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
We thank Sean Jedrzkiewicz and Anna Woo and the
Echocardiography Laboratory of the Toronto General Hospital for
providing the echo images (Figures 1–3), and James Pullman of the
Montefiore Medical Center Department of Pathology for providing
the autopsy image (Figure 4) used in this paper.
REFERENCES
1. Moss AH, McLaughlin MM, Lempert KD et al. Use of a silicone catheter
with a Dacron cuff for dialysis short-term vascular access. Am J Kidney
Dis 1988; 12: 492–498.
2. Schwab SJ, Buller GL, McCann RL et al. Prospective evaluation of a
Dacron cuffed hemodialysis catheter for prolonged use. Am J Kidney Dis
1988; 11: 166–169.
3. Shusterman NH, Kloss K, Mullen JL. Successful use of double-lumen,
silicone rubber catheters for permanent hemodialysis access. Kidney Int
1989; 35: 887–890.
4. CORR 2010 CORR Report—Treatment of End-Stage Organ Failure in
Canada, 1999 to 2008, 2010.
5. USRDS: US Renal Data System. USRDS 2009 Annual Data Report: Atlas of
Chronic Kidney Disease and End-Stage Renal Disease in the United
States, National Institutes of Health. National Institute of Diabetes and
Digestive and Kidney Diseases: Bethesda, MD, 2009.
6. USRDS: US Renal Data System. USRDS 2009 Annual Data Report: Atlas of
Chronic Kidney Disease and End-Stage Renal Disease in the United
States, National Institutes of Health. National Institute of Diabetes
and Digestive and Kidney Diseases: Bethesda, MD, 2009, Figure 6.4,
Chapter 6, pp 273.
7. Thomson PC, Stirling CM, Geddes CC et al. Vascular access in
haemodialysis patients: a modifiable risk factor for bacteraemia and
death. QJM 2007; 100: 415–422.
8. Ishani A, Collins AJ, Herzog CA et al. Septicemia, access and
cardiovascular disease in dialysis patients: the USRDS Wave 2 study.
Kidney Int 2005; 68: 311–318.
9. Engemann JJ, Friedman J, Reed SD et al. Clinical outcomes and costs
due to Staphylococcus aureus bacteremia among patients receiving
long-term hemodialysis. Infect Control Hosp Epidemiol 2005; 26:
534–539.
10. Marr KA, Kong L, Fowler VG et al. Incidence and outcome of
Staphylococcus aureus bacteremia in hemodialysis patients. Kidney Int
1998; 54: 1684–1689.
11. Maraj S, Jacobs LE, Kung SC et al. Epidemiology and outcome of infective
endocarditis in hemodialysis patients. Am J Med Sci 2002; 324: 254–260.
12. Ramanathan V, Chiu EJ, Thomas JT et al. Healthcare costs associated
with hemodialysis catheter-related infections: a single-center
experience. Infect Control Hosp Epidemiol 2007; 28: 606–609.
13. Mokrzycki MH, Zhang M, Cohen H et al. Tunnelled haemodialysis
catheter bacteraemia: risk factors for bacteraemia recurrence, infectious
complications and mortality. Nephrol Dial Transplant 2006; 21:
1024–1031.
14. Tanriover B, Carlton D, Saddekni S et al. Bacteremia associated with
tunneled dialysis catheters: comparison of two treatment strategies.
Kidney Int 2000; 57: 2151–2155.
15. Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the
diagnosis and management of intravascular catheter-related infection:
2009 Update by the Infectious Diseases Society of America. Clin Infect
Dis 2009; 49: 1–45.
16. CDC. http://www.cdc.gov/nhsn/PDFs/pscManual/8pscDialysisEvent
current.pdf. vol 2010, Dialysis Event Reporting 2010.
17. Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in
adults with different intravascular devices: a systematic review of 200
published prospective studies. Mayo Clin Proc 2006; 81: 1159–1171.
18. Tokars JI. Description of a new surveillance system for bloodstream and
vascular access infections in outpatient hemodialysis centers. Semin Dial
2000; 13: 97–100.
19. Taylor G, Gravel D, Johnston L et al. Prospective surveillance for primary
bloodstream infections occurring in Canadian hemodialysis units.
Infect Control Hosp Epidemiol 2002; 23: 716–720.
20. Vascular Access Work Group. Clinical Practice Guidelines for Vascular
Access. Am J Kidney Dis 2006; 48: S176–S247.
21. Jindal K, Chan CT, Deziel C et al. Hemodialysis clinical practice guidelines
for the Canadian Society of Nephrology. Chapter 4: vascular access.
J Am Soc Nephrol 2006; 17(Suppl 1): S16–S23.
22. Vanholder R, Canaud B, Fluck R et al. Diagnosis, prevention and
treatment of haemodialysis catheter-related bloodstream infections
(CRBSI): a position statement of European Renal Best Practice (ERBP).
NDT Plus 2010; 25: 1753–1756.
23. George A, Tokars JI, Clutterbuck EJ et al. Reducing dialysis associated
bacteraemia, and recommendations for surveillance in the United
Kingdom: prospective study. BMJ 2006; 332: 1435.
24. Saad TF. Bacteremia associated with tunneled, cuffed hemodialysis
catheters. Am J Kidney Dis 1999; 34: 1114–1124.
25. Krishnasami Z, Carlton D, Bimbo L et al. Management of hemodialysis
catheter-related bacteremia with an adjunctive antibiotic lock solution.
Kidney Int 2002; 61: 1136–1142.
26. Onder AM, Chandar J, Simon N et al. Comparison of tissue plasminogen
activator-antibiotic locks with heparin-antibiotic locks in children with
catheter-related bacteraemia. Nephrol Dial Transplant 2008; 23:
2604–2610.
27. Lok CE, Stanley KE, Hux JE et al. Hemodialysis infection prevention with
polysporin ointment. J Am Soc Nephrol 2003; 14: 169–179.
28. Johnson DW, MacGinley R, Kay TD et al. A randomized controlled
trial of topical exit site mupirocin application in patients with tunnelled,
cuffed haemodialysis catheters. Nephrol Dial Transplant 2002; 17:
1802–1807.
29. Johnson DW, van Eps C, Mudge DW et al. Randomized, controlled trial of
topical exit-site application of honey (Medihoney) versus mupirocin for
the prevention of catheter-associated infections in hemodialysis
patients. J Am Soc Nephrol 2005; 16: 1456–1462.
30. Weijmer MC, van den Dorpel M, Van de Ven PJ, et al., CITRATE Study
Group. Randomized, clinical trial comparison of trisodium citrate 30 and
heparin as catheter-locking solution in hemodialysis patients. J Am Soc
Nephrol 2005; 16: 2769–2777.
31. Power A, Duncan N, Singh SK. Sodium citrate versus heparin catheter
locks for cuffed central venous catheters: a single-center randomized
controlled trial. Am J Kidney Dis 2009; 53: 1034–1041.
32. Ash SR, Maki DG, Lavin PT et al. A multi-center randomized trial
of an antimicrobial and antithrombotic lock solution for hemodialysis
catheters (abstract). J Am Soc Nephrol 2009, available at http://
www.abstracts2view.com/asn09/.
33. Solomon LR, Cheesbrough JS, Ebah L et al. A randomized double-blind
controlled trial of taurolidine-citrate catheter locks for the prevention of
bacteremia in patients treated with hemodialysis (in press). Am J Kidney
Dis 2010; 55: 1060–1068.
Kidney International (2011) 79, 587–598 595
CE Lok and MH Mokrzycki: Prevention and management of catheter-related infection rev iew
34. Beathard GA. Management of bacteremia associated with tunneled-
cuffed hemodialysis catheters. J Am Soc Nephrol 1999; 10: 1045–1049.
35. Allon M. Prophylaxis against dialysis catheter-related bacteremia
with a novel antimicrobial lock solution. Clin Infect Dis 2003; 36:
1539–1544.
36. Saeed Abdulrahman I, Al-Mueilo SH, Bokhary HA. et al. A prospective
study of hemodialysis access-related bacterial infections. J Infect
Chemother 2002; 8: 242–246.
37. Marr KA, Sexton DJ, Conlon PJ et al. Catheter-related bacteremia and
outcome of attempted catheter salvage in patients undergoing
hemodialysis. Ann Intern Med 1997; 127: 275–280.
38. Taylor G, Gravel D, Johnston L et al. Incidence of bloodstream infection
in multicenter inception cohorts of hemodialysis patients. Am J Infect
Control 2004; 32: 155–160.
39. Tokars JI, Light P, Anderson J et al. A prospective study of vascular
access infections at seven outpatient hemodialysis centers. Am J Kidney
Dis 2001; 37: 1232–1240.
40. Lemaire X, Morena M, Leray-Moragues H et al. Analysis of risk factors
for catheter-related bacteremia in 2000 permanent dual catheters for
hemodialysis. Blood Purif 2009; 28: 21–28.
41. Jean G, Charra B, Chazot C et al. Risk factor analysis for long-term tunneled
dialysis catheter-related bacteremias. Nephron 2002; 91: 399–405.
42. Negulescu O, Coco M, Croll J et al. Large atrial thrombus formation
associated with tunneled cuffed hemodialysis catheters. Clin Nephrol
2003; 59: 40–46.
43. Poole CV, Carlton D, Bimbo L et al. Treatment of catheter-related
bacteraemia with an antibiotic lock protocol: effect of bacterial
pathogen. Nephrol Dial Transplant 2004; 19: 1237–1244.
44. Kovalik EC, Raymond JR, Albers FJ et al. A clustering of epidural
abscesses in chronic hemodialysis patients: risks of salvaging
access catheters in cases of infection. J Am Soc Nephrol 1996; 7:
2264–2267.
45. Ghani MK, Boccalandro F, Denktas AE et al. Right atrial thrombus
formation associated with central venous catheters utilization in
hemodialysis patients. Intensive Care Med 2003; 29: 1829–1832.
46. Obrador GT, Levenson DJ. Spinal epidural abscess in hemodialysis
patients: report of three cases and review of the literature. Am J Kidney
Dis 1996; 27: 75–83.
47. Philipneri M, Al-Aly Z, Amin K et al. Routine replacement of tunneled,
cuffed, hemodialysis catheters eliminates paraspinal/vertebral infections
in patients with catheter-associated bacteremia. Am J Nephrol 2003; 23:
202–207.
48. Nielsen J, Ladefoged SD, Kolmos HJ. Dialysis catheter-related
septicaemia–focus on Staphylococcus aureus septicaemia. Nephrol Dial
Transplant 1998; 13: 2847–2852.
49. Levin A, Mason AJ, Jindal KK et al. Prevention of hemodialysis subclavian
vein catheter infections by topical povidone-iodine. Kidney Int 1991; 40:
934–938.
50. Sesso R, Barbosa D, Leme IL et al. Staphylococcus aureus prophylaxis in
hemodialysis patients using central venous catheter: effect of mupirocin
ointment. J Am Soc Nephrol 1998; 9: 1085–1092.
51. Johnson LB, Jose J, Yousif F et al. Prevalence of colonization with
community-associated methicillin-resistant Staphylococcus aureus
among end-stage renal disease patients and healthcare workers.
Infect Control Hosp Epidemiol 2009; 30: 4–8.
52. Boelaert JR, De Smedt RA, De Baere YA et al. The influence of calcium
mupirocin nasal ointment on the incidence of Staphylococcus aureus
infections in haemodialysis patients. Nephrol Dial Transplant 1989; 4:
278–281.
53. Kluytmans JA, Manders MJ, van Bommel E et al. Elimination of nasal
carriage of Staphylococcus aureus in hemodialysis patients. Infect
Control Hosp Epidemiol 1996; 17: 793–797.
54. Danese MD, Griffiths R, Dylan M et al. Mortality differences among
organisms causing septicemia in hemodialysis patients. Hemodial Int
2006; 10: 56–62.
55. von Eiff C, Jansen B, Kohnen W et al. Infections associated with medical
devices: pathogenesis, management and prophylaxis. Drugs 2005; 65:
179–214.
56. Nissenson AR, Dylan ML, Griffiths RI et al. Clinical and economic
outcomes of Staphylococcus aureus septicemia in ESRD patients
receiving hemodialysis. Am J Kidney Dis 2005; 46: 301–308.
57. Lentino JR, Baddour LM, Wray M et al. Staphylococcus aureus and other
bacteremias in hemodialysis patients: antibiotic therapy and surgical
removal of access site. Infection 2000; 28: 355–360.
58. Inrig JK, Reed SD, Szczech LA et al. Relationship between clinical
outcomes and vascular access type among hemodialysis patients with
Staphylococcus aureus bacteremia. Clin J Am Soc Nephrol 2006; 1:
518–524.
59. Reed SD, Friedman JY, Engemann JJ et al. Costs and outcomes among
hemodialysis-dependent patients with methicillin-resistant or
methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control
Hosp Epidemiol 2005; 26: 175–183.
60. Golestaneh L, Laut J, Rosenberg S et al. Favourable outcomes in
episodes of Pseudomonas bacteraemia when associated with tunnelled
cuffed catheters (TCCs) in chronic haemodialysis patients. Nephrol Dial
Transplant 2006; 21: 1328–1333.
61. Onder AM, Chandar J, Simon N et al. Treatment of catheter-related
bacteremia with tissue plasminogen activator antibiotic locks. Pediatr
Nephrol 2008; 23: 457–464.
62. Cheesbrough JS, Finch RG, Burden RP. A prospective study of the
mechanisms of infection associated with hemodialysis catheters.
J Infect Dis 1986; 154: 579–589.
63. Hoshal Jr VL, Ause RG, Hoskins PA. Fibrin sleeve formation on
indwelling subclavian central venous catheters. Arch Surg 1971; 102:
253–258.
64. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common
cause of persistent infections. Science 1999; 284: 1318–1322.
65. Donlan RM. Biofilm formation: a clinically relevant microbiological
process. Clin Infect Dis 2001; 33: 1387–1392.
66. Kanaa M, Wright MJ, Sandoe JA. Examination of tunnelled haemodialysis
catheters using scanning electron microscopy. Clin Microbiol Infect 2010;
16: 780–786.
67. Raad I, Costerton W, Sabharwal U. et al. Ultrastructural analysis of
indwelling vascular catheters: a quantitative relationship between
luminal colonization and duration of placement. J Infect Dis 1993; 168:
400–407.
68. Tapia G, Yee J. Biofilm: its relevance in kidney disease. Adv Chronic
Kidney Dis 2006; 13: 215–224.
69. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms.
Lancet 2001; 358: 135–138.
70. Fux CA, Costerton JW, Stewart PS et al. Survival strategies of infectious
biofilms. Trends Microbiol 2005; 13: 34–40.
71. Lee DH, Jung KY, Choi YH. Use of maximal sterile barrier precautions
and/or antimicrobial-coated catheters to reduce the risk of central
venous catheter-related bloodstream infection. Infect Control Hosp
Epidemiol 2008; 29: 947–950.
72. Raad I, Hohn DC, Gilbreath BJ et al. Prevention of central venous
catheter-related infections by using maximal sterile barrier
precautions during insertion. Infect Control Hosp Epidemiol 1994; 15:
231–238.
73. Ishizuka M, Nagata H, Takagi K et al. Comparison of 0.05% chlorhexidine
and 10% povidone-iodine as cutaneous disinfectant for prevention of
central venous catheter-related bloodstream infection: a comparative
study. Eur Surg Res 2009; 43: 286–290.
74. McCann M, Moore ZE. Interventions for preventing infectious
complications in haemodialysis patients with central venous catheters.
Cochrane Database Systematic Review 2010; 20(1): CD00689.
75. Onder AM, Chandar J, Billings A et al. Chlorhexidine-based antiseptic
solutions effectively reduce catheter-related bacteremia. Pediatr Nephrol
2009; 24: 1741–1747.
76. Darouiche RO, Wall Jr MJ, Itani KM et al. Chlorhexidine-alcohol versus
povidone-iodine for surgical-site antisepsis. N Engl J Med 2010; 362:
18–26.
77. Paocharoen V, Mingmalairak C, Apisarnthanarak A. Comparison of
surgical wound infection after preoperative skin preparation
with 4% chlorhexidine [correction of chlohexidine] and povidone
iodine: a prospective randomized trial. J Med Assoc Thai 2009; 92:
898–902.
78. Valles J, Fernandez I, Alcaraz D et al. Prospective randomized trial of
3 antiseptic solutions for prevention of catheter colonization in an
intensive care unit for adult patients. Infect Control Hosp Epidemiol 2008;
29: 847–853.
79. Mimoz O, Villeminey S, Ragot S et al. Chlorhexidine-based antiseptic
solution vs alcohol-based povidone-iodine for central venous catheter
care. Arch Intern Med 2007; 167: 2066–2072.
80. Chaiyakunapruk N, Veenstra DL, Lipsky BA et al. Chlorhexidine
compared with povidone-iodine solution for vascular catheter-site care:
a meta-analysis. Ann Intern Med 2002; 136: 792–801.
81. Maki DG, Ringer M. Evaluation of dressing regimens for prevention of
infection with peripheral intravenous catheters. Gauze, a transparent
polyurethane dressing, and an iodophor-transparent dressing.
JAMA 1987; 258: 2396–2403.
596 Kidney International (2011) 79, 587–598
rev iew CE Lok and MH Mokrzycki: Prevention and management of catheter-related infection
82. Hoffmann KK, Weber DJ, Samsa GP et al. Transparent polyurethane
film as an intravenous catheter dressing. A meta-analysis of the
infection risks. JAMA 1992; 267: 2072–2076.
83. Gilles D, O’Riordan L, Carr D et al. Gauze and tape and transparent
polyurethane dressings for central venous catheters. Cochrane Database
Systematic Review 2003; 4: CD00382.
84. Le Corre I, Delorme M, Cournoyer S. A prospective, randomized trial
comparing a transparent dressing and a dry gauze on the exit site of
long term central venous catheters of hemodialysis patients. J Vasc
Access 2003; 4: 56–61.
85. Battistella M, Bhola C, Lok CE. Long-term follow-up of the Hemodialysis
Infection Prevention with Polysporin Ointment (HIPPO) Study: a quality
improvement report. Am J Kidney Dis (in press).
86. Molan PC. The antibacterial nature of honey. 1. The nature of the
antibacterial activity. Bee World 1992; 73: 5–28.
87. Kwakman PH, Van den Akker JP, Guclu A et al. Medical-grade honey
kills antibiotic-resistant bacteria in vitro and eradicates skin colonization.
Clin Infect Dis 2008; 46: 1677–1682.
88. Bloom BS, Fendrick AM, Chernew ME et al. Clinical and economic effects
of mupirocin calcium on preventing Staphylococcus aureus infection in
hemodialysis patients: a decision analysis. Am J Kidney Dis 1996; 27:
687–694.
89. Tacconelli E, Carmeli Y, Aizer A et al. Mupirocin prophylaxis to prevent
Staphylococcus aureus infection in patients undergoing dialysis: a
meta-analysis. Clin Infect Dis 2003; 37: 1629–1638.
90. Perez-Fontan M, Rosales M, Rodriguez-Carmona A et al. Mupirocin
resistance after long-term use for Staphylococcus aureus colonization in
patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002;
39: 337–341.
91. Annigeri R, Conly J, Vas S et al. Emergence of mupirocin-resistant
Staphylococcus aureus in chronic peritoneal dialysis patients using
mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 2001;
21: 554–559.
92. Lobbedez T, Gardam M, Dedier H et al. Routine use of mupirocin at the
peritoneal catheter exit site and mupirocin resistance: still low after
7 years. Nephrol Dial Transplant 2004; 19: 3140–3143.
93. James MT, Conley J, Tonelli M et al. Meta-analysis: antibiotics for
prophylaxis against hemodialysis catheter-related infections. Ann Intern
Med 2008; 148: 596–605.
94. Yahav D, Rozen-Zvi B, Gafter-Gvili A et al. Antimicrobial lock solutions
for the prevention of infections associated with intravascular
catheters in patients undergoing hemodialysis: systematic review and
meta-analysis of randomized, controlled trials. Clin Infect Dis 2008; 47:
83–93.
95. Jaffer Y, Selby NM, Taal MW et al. A meta-analysis of hemodialysis
catheter locking solutions in the prevention of catheter-related
infection. Am J Kidney Dis 2008; 51: 233–241.
96. Snaterse M, Ruger W, Scholte OP et al. Antibiotic-based catheter lock
solutions for prevention of catheter-related bloodstream infection: a
systematic review of randomised controlled trials. J Hosp Infect 2010; 75:
1–11.
97. Pervez A, AhmedM, Ram S et al. Antibiotic lock technique for prevention of
cuffed tunnel catheter associated bacteremia. J Vasc Access 2002; 3:
108–113.
98. Landry DL, Sweet SJ, Gobeille SL et al. Long-term gentamicin lock
catheter prophylaxis is associated with with gentamicin-resistant
Gram-positive bacteremias in chronic hemodialysis (abstract).
J Am Soc Nephrol 2009, available at http://www.abstracts2view.com/
asn09/.
99. Shanks RMQ, Sargent JL, Martinez RM et al. Catheter lock solutions
influence staphylococcal biofilm formation on abiotic surfaces. Nephrol
Dial Transplant 2006; 21: 2247–2255.
100. Bosma JW, Siegert CE, Peerbooms PG et al. Reduction of biofilm formation
with trisodium citrate in haemodialysis catheters: a randomized controlled
trial. Nephrol Dial Transplant 2010; 25: 1213–1217.
101. Sauer K, Steczko J, Ash SR. Effect of a solution containing citrate/
methylene blue/parabens on Staphylococcus aureus bacteria and
biofilm, and comparison with various heparin solutions. J Antimicrob
Chemother 2009; 63: 937–945.
102. Balestrino D, Souweine B, Charbonnel N et al. Eradication of
microorganisms embedded in biofilm by an ethanol-based catheter lock
solution. Nephrol Dial Transplant 2009; 24: 3204–3209.
103. Takla TA, Zelenitsky SA, Vercaigne LM. Effectiveness of a 30% ethanol/
4% trisodium citrate locking solution in preventing biofilm formation by
organisms causing haemodialysis catheter-related infections.
J Antimicrob Chemother 2008; 62: 1024–1026.
104. Raad II, Fang X, Keutgen XM et al. The role of chelators in preventing
biofilm formation and catheter-related bloodstream infections.
Curr Opin Infect Dis 2008; 21: 385–392.
105. Percival SL, Kite P, Eastwood K et al. Tetrasodium EDTA as a novel central
venous catheter lock solution against biofilm. Infect Control Hosp
Epidemiol 2005; 26: 515–519.
106. Shah CB, Mittelman MW, Costerton JW et al. Antimicrobial activity of a
novel catheter lock solution. Antimicrob Agents Chemother 2002; 46:
1674–1679.
107. Raad I, Hanna H, Dvorak T et al. Optimal antimicrobial catheter lock
solution, using different combinations of minocycline, EDTA, and
25-percent ethanol, rapidly eradicates organisms embedded in biofilm.
Antimicrob Agents Chemother 2007; 51: 78–83.
108. Betjes MG, van Agteren M. Prevention of dialysis catheter-related sepsis
with a citrate-taurolidine-containing lock solution. Nephrol Dial
Transplant 2004; 19: 1546–1551.
109. Venditto M, Tezenas du Montcel S, Robert J et al. Effect of catheter-lock
solutions on catheter-related infection and inflammatory syndrome in
hemodialysis patients: heparin versus citrate 46% versus heparin/
gentamicin. Blood Purif 2010; 29: 268–273.
110. Winnett G, Nolan J, Miller M et al Trisodium citrate 46.7% selectively and
safely reduces staphylococcal catheter-related bacteraemia. Nephrol Dial
Transplant 2008; 23: 3592–3598.
111. FDA: Food and Drug Administration. FDA issues warning on triCitrasol
dialysis catheter anticoagulant. In: FDA Talk Paper, vol 14 2000,
pp T00–16.
112. Willicombe MK, Vernon K, Davenport A. Embolic complications from
central venous hemodialysis catheters used with hypertonic citrate
locking solution. Am J Kidney Dis 2010; 55: 348–351.
113. Qu Y, Istivan TS, Daley AJ et al. Comparison of various antimicrobial
agents as catheter lock solutions: preference for ethanol in eradication
of coagulase-negative staphylococcal biofilms. J Med Microbiol 2009; 58:
442–450.
114. Rosenbauer KA. Light microscopic and scanning electron microscopic
findings on intravenous polyurethane catheters. Scan Electron Microsc
1982; Pt2: 765–772.
115. Franson TR, Sheth NK, Rose HD et al. Scanning electron microscopy of
bacteria adherent to intravascular catheters. J Clin Microbiol 1984; 20:
500–505.
116. Verbeke F, Haug U, Dhondt A et al. The role of polymer surface
degradation and barium sulphate release in the pathogenesis of
catheter-related infection. Nephrol Dial Transplant 2010; 25:
1207–1213.
117. Darouiche RO, Raad II, Heard SO et al. A comparison of two
antimicrobial-impregnated central venous catheters. Catheter Study
Group. N Engl J Med 1999; 340: 1–8.
118. Rupp ME, Lisco SJ, Lipsett PA et al. Effect of a second-generation venous
catheter impregnated with chlorhexidine and silver sulfadiazine on
central catheter-related infections: a randomized, controlled trial.
Ann Intern Med 2005; 143: 570–580.
119. Veenstra DL, Saint S, Saha S et al. Efficacy of antiseptic-impregnated
central venous catheters in preventing catheter-related bloodstream
infection: a meta-analysis. JAMA 1999; 281: 261–267.
120. Maki DG, Stolz SM, Wheeler S et al. Prevention of central venous
catheter-related bloodstream infection by use of an antiseptic-
impregnated catheter. A randomized, controlled trial. Ann Intern Med
1997; 127: 257–266.
121. Trerotola SO, Johnson MS, Shah H et al. Tunneled hemodialysis
catheters: use of a silver-coated catheter for prevention of infection—
a randomized study. Radiology 1998; 207: 491–496.
122. Domenico P, Gurzenda E, Giacometti A et al. BisEDT and RIP act in
synergy to prevent graft infections by resistant staphylococci. Peptides
2004; 25: 2047–2053.
123. Huang CT, Stewart PS. Reduction of polysaccharide production in
Pseudomonas aeruginosa biofilms by bismuth dimercaprol (BisBAL)
treatment. J Antimicrob Chemother 1999; 44: 601–605.
124. Schindler R, Heemann U, Haug U et al. Bismuth coating of
non-tunneled haemodialysis catheters reduces bacterial colonization:
a randomized controlled trial. Nephrol Dial Transplant 2010; 25:
2651–2656.
125. Jain G, Allon M, Saddekni S et al. Does heparin coating improve patency
or reduce infection of tunneled dialysis catheters? Clin J Am Soc Nephrol
2009; 4: 1787–1790.
126. Mojibian H, Spector M, Ni N et al. Initial clinical experience with a new
heparin-coated chronic hemodialysis catheter. Hemodial Int 2009; 13:
329–334.
Kidney International (2011) 79, 587–598 597
CE Lok and MH Mokrzycki: Prevention and management of catheter-related infection rev iew
127. Panais R, Hirsch DJ, Dipchand C et al. A protocolized approach to
vancomycin dosing in conventional hemodialysis. J Nephrol 2010; 23:
569–574.
128. Barth RH, DeVincenzo N. Use of vancomycin in high-flux
hemodialysis: experience with 130 courses of therapy. Kidney Int
1996; 50: 929–936.
129. Mason NA, Neudeck BL, Welage LS et al. Comparison of 3 vancomycin
dosage regimens during hemodialysis with cellulose triacetate dialyzers:
post-dialysis versus intradialytic administration. Clin Nephrol 2003; 60:
96–104.
130. Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and
bactericidal activity to efficacy of vancomycin for treatment of
methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol
2004; 42: 2398–2402.
131. Stryjewski ME, Szczech LA, Benjamin DK et al. Use of vancomycin or
first-generation cephalosporins for the treatment of hemodialysis-
dependent patients with methicillin-susceptible Staphylococcus aureus
bacteremia. Clin Infect Dis 2007; 44: 190–196.
132. Ashby DR, Power A, Singh S et al. Bacteremia associated with tunneled
hemodialysis catheters: outcome after attempted salvage. Clin J Am Soc
Nephrol 2009; 4: 1601–1605.
133. Capdevila JA, Segarra A, Planes AM et al. Successful treatment of
haemodialysis catheter-related sepsis without catheter removal.
Nephrol Dial Transplant 1993; 8: 231–234.
134. Mokrzycki MH, Singhal A. Cost-effectiveness of three strategies of
managing tunnelled, cuffed haemodialysis catheters in clinically mild
or asymptomatic bacteraemias. Nephrol Dial Transplant 2002; 17:
2196–2203.
135. Mokrzycki MH, Zhang M, Golestaneh L et al. An interventional controlled
trial comparing 2 management models for the treatment of tunneled
cuffed catheter bacteremia: a collaborative team model versus usual
physician-managed care. Am J Kidney Dis 2006; 48: 587–595.
136. Shiell KA, Makanjoula D, Steele M et al. A multidisciplinary catheter care
team reduces the risk of tunneled central venous catheter loss due to
infection and improves cather survival at 6 months (abstract). J Am Soc
Nephrol 2008, available at http://www.abstracts2view.com/asn08/.
137. Polkinghorne KR, Seneviratne M, Kerr PG. Effect of a vascular access
nurse coordinator to reduce central venous catheter use in incident
hemodialysis patients: a quality improvement report. Am J Kidney Dis
2009; 53: 99–106.
138. Kingdon EJ, Holt SG, Davar J et al. Atrial thrombus and central venous
dialysis catheters. Am J Kidney Dis 2001; 38: 631–639.
139. Shah A, Murray M, Nzerue C. Right atrial thrombi complicating use of
central venous catheters in hemodialysis. Int J Artif Organs 2004; 27:
772–778.
140. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:
520–532.
141. Stanley K. Design of randomized controlled trials. Circulation 2007; 115:
1164–1169.
142. Dogra GK, Herson H, Hutchison B et al. Prevention of tunneled
hemodialysis catheter-related infections using catheter-restricted filling
with gentamicin and citrate: a randomized controlled study. J Am Soc
Nephrol 2002; 13: 2133–2139.
143. McIntyre CW, Hulme LJ, Taal M et al. Locking of tunneled
hemodialysis catheters with gentamicin and heparin. Kidney Int 2004;
66: 801–805.
144. Nori US, Manoharan A, Yee J et al. Comparison of low-dose gentamicin
with minocycline as catheter lock solutions in the prevention of
catheter-related bacteremia. Am J Kidney Dis 2006; 48: 596–605.
145. Onder AM, Chandar J, Billings A et al. Prophylaxis of catheter-related
bacteremia using tissue plasminogen activator-tobramycin locks.
Pediatr Nephrol 2009; 24: 2233–2243.
146. Bleyer AJ, Mason L, Russell G et al. A randomized, controlled trial
of a new vascular catheter flush solution (minocycline-EDTA) in
temporary hemodialysis access. Infect Control Hosp Epidemiol 2005;
26: 520–524.
147. Saxena AK, Panhotra BR. The impact of catheter-restricted filling
with cefotaxime and heparin on the lifespan of temporary
hemodialysis catheters: a case controlled study. J Nephrol 2005; 18:
755–763.
148. Saxena AK, Panhotra BR, Sundaram DS et al. Enhancing the survival of
tunneled haemodialysis catheters using an antibiotic lock in the elderly:
a randomised, double-blind clinical trial. Nephrology (Carlton) 2006; 11:
299–305.
149. Al-Hwiesh A, Abdul-Rahman I. Successful prevention of tunneled,
central catheter infection by antibiotic lock therapy using vancomycin
and gentamycin. Saudi J Kidney Dis Transplant 2007; 18: 239–247.
150. Kim SH, Song KI, Chang JW et al. Prevention of uncuffed hemodialysis
catheter-related bacteremia using an antibiotic lock technique: a
prospective, randomized clinical trial. Kidney Int 2006; 69: 161–164.
151. Beigi AA, Khansoltani S, Masoudpour H et al. Influence of intralumenal
and antibiotic-lock of vancomycin on the rate of catheter removal in the
patients with permanent hemodialysis catheters. Saudi J Kidney Dis
Transplant 2010; 21: 54–58.
598 Kidney International (2011) 79, 587–598
rev iew CE Lok and MH Mokrzycki: Prevention and management of catheter-related infection
